Vimarsana
Biggest News Aggregation in the World

Page 23 - Pfizer Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pfizer Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pfizer Ventures Today - Breaking & Trending Today

Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration - Vimarsana News

Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration

Novartis, Artios Pharma Target Cancer in Up-to-$1.3B DDR Collaboration April 7, 2021 Share Artios Pharma CEO Niall Martin, PhD Novartis has agreed to identify and validate next-generation DNA Damage Response (DDR) targets for precision cancer treatments using Artios Pharma’s discovery platform, through a collaboration that could generate more than $1.3 billion for Artios. The companies plan to discover and validate targets that enhance Novartis’ Radioligand Therapies (RLTs) through a three-year research collaboration. Novartis will select up to three exclusive DDR targets, and receive wor...

Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie - Vimarsana News

Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie

Share this article Share this article SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, announced today that AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin's lead PINK1 compound. Based on technology discovered at UCSF by Mitokinin co-founders Nicholas Hertz and Kevan Shokat, Mitokinin moved into MBC BioLabs San Francisco in September 2017 with Series A fu...

Palleon Pharmaceuticals Appoints Nikola Trbovic to Its Board of Directors - Vimarsana News

Palleon Pharmaceuticals Appoints Nikola Trbovic to Its Board of Directors

Posted on 394 Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the appointment of Nikola Trbovic, Ph.D., Executive Director and Partner at Pfizer Ventures, as a member of its Board of Directors. “Nikola’s expertise in R&D and corporate finance will be an asset to Palleon, and we are very pleased to welcome him to the Board. Nikola will replace Bill Burkoth, who we would like to thank for the valuable support and guidance that ...

BioAtla Is the Latest Biotech IPO to Pop. It Closed Up 72%. - Vimarsana News

BioAtla Is the Latest Biotech IPO to Pop. It Closed Up 72%.

BioAtla’s (ticker: BCAB) gain came even after the company increased the size of its deal, selling 10.5 million shares at $18. This is up from the 9.4 million shares at $15 to $17 each it had planned to sell. Credit Suisse are underwriters on the deal. BioAtla is developing antibody-based therapeutics to treat solid tumor cancers. The San Diego company has two product candidates, BA3011 and BA302, that are in Phase 2 trials. Like many biotechs, BioAtla is not profitable. It does not have any treatments approved for commercial sale and hasn’t generated any revenue from product sales...